Regeneron Pharmaceuticals, Inc. (BIT:1REGN)

Market Cap	49.43B
Revenue (ttm)	12.10B
Net Income (ttm)	3.80B
Shares Out	n/a
EPS (ttm)	33.78
PE Ratio	13.02
Forward PE	13.30
Dividend	1.63 (0.34%)
Ex-Dividend Date	May 19, 2025

Volume	1
Average Volume	13
Open	488.30
Previous Close	481.60
Day's Range	476.60 - 488.30
52-Week Range	418.00 - 1,094.50
Beta	n/a
RSI	48.53
Earnings Date	Aug 1, 2025

About Veren

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 15,106
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1REGN

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in CAD